Twitter | Pretraživanje | |
Xconomy
. Ends Hepatitis B Work After Death in Clinical Trial - by
Spring Bank Pharmaceuticals is stopping work on an experimental treatment for hepatitis B virus after serious side effects, including one patient death,
Xconomy Xconomy @Xconomy
Reply Retweet Označi sa "sviđa mi se" More
Mariano 29. sij
“Spring Bank has started discussion for outlicensing it’s chimeric oligonucleotide program for Hepatitis B virus” Why?
Reply Retweet Označi sa "sviđa mi se"